BioTime, Inc. Reports Third Quarter Results and Recent Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Crude Inventory Fell 4.5M Barrels Last Week - EIA
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- TScan cuts 75% of workforce, pivots to solid tumor cell therapy
BioTime (BTX) Posts Q3 EPS of 30c
November 4, 2016 9:20 AM EDTBioTime (NYSE: BTX) reported Q3 EPS of $0.30, which may not compare with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.23 million.
Profitability was largely due to a fain on equity method investment in... More
